Bryce Einhorn
Interventional Cardiology · Lewiston, MENPI 1891140158
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,470 of the $4,588 with a category attached, or 75.6%. It is spread thinly across 25 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,294 and has fallen 77.3% since, to $294 in 2025.
Across 142 payments — averaging $32.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$899
- AstraZeneca$517
- Johnson & Johnson$486
- Abbott$481
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$272
- Novartis$246
- plus $2K from 19 others
What the payments were for
- Travel & lodging$3608%
- Food & beverage$3,47076%
- Education$68315%
- Gifts$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 13 | $899 |
| AstraZeneca | 22 | $517 |
| Johnson & Johnson | 18 | $486 |
| Abbott | 10 | $481 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $272 |
| Novartis | 15 | $246 |
| Medtronic(2 entities) | 4 | $236 |
| Chiesi USA, Inc. | 7 | $220 |
| Astellas Pharma US Inc | 2 | $198 |
| Amgen | 10 | $195 |
| Abiomed | 7 | $161 |
| Cardiovascular Systems Inc. | 1 | $148 |
| Lantheus Medical Imaging, Inc. | 3 | $81 |
| Boehringer Ingelheim | 3 | $81 |
| Pfizer | 3 | $66 |
| Boston Scientific | 2 | $65 |
| Acacia Pharma Inc | 2 | $39 |
| Novo Nordisk | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Teleflex LLC | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Bayer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,588 in reported general payments places this provider in the 75th percentile of 21 interventional cardiology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 60 | $93,476 |
| EliquisApixaban | 52 | $71,455 |
| JardianceEmpagliflozin | 38 | $63,931 |
| FarxigaDapagliflozin Propanediol | 25 | $33,095 |
| XareltoRivaroxaban | 22 | $30,684 |
| Repatha SureclickEvolocumab | 36 | $28,141 |
| Repatha SyringeEvolocumab | 23 | $13,890 |
| Metoprolol Succinate | 146 | $2,476 |
| Ranolazine ErRanolazine | 12 | $1,860 |
| Ezetimibe | 64 | $1,628 |
| Rosuvastatin Calcium | 50 | $1,166 |
| Carvedilol | 90 | $1,147 |
| Atorvastatin Calcium | 93 | $889 |
| Bumetanide | 13 | $682 |
| Valsartan | 19 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $246 | $93,47660 claims |
| PfizerEliquis | $66 | $71,45552 claims |
| Boehringer IngelheimJardiance | $81 | $63,93138 claims |
| AstraZenecaFarxiga | $517 | $33,09525 claims |
| Johnson & JohnsonXarelto | $486 | $30,68422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 interventional cardiology providers in Maine.
Other interventional cardiology in Lewiston
- Arun ThukkaniLewiston$8K
- Peter HigginsLewiston$4K
- Andrew EisenhauerLewiston$2K
- Michael BerlowitzLewiston$631
- Szymon WiernekScarborough$22K
- Srikanth RadhakrishnanBangor$7K
- Ellie MuellerAugusta$6K
- Jay ShahScarborough$5K
- Matthew McKayBangor$4K
- Thomas EarlBangor$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.